News
6d
TipRanks on MSNRegeneron and Sanofi’s Itepekimab Study: A Potential Game-Changer for COPD Treatment
The recent clinical study update from Regeneron Pharmaceuticals and Sanofi focuses on the investigation of Itepekimab, an anti-IL-33 monoclonal antibody, to understand its effects ...
7d
TipRanks on MSNAstraZeneca’s Benralizumab Study Completes: A Potential Game-Changer for COPD Treatment
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inhaled chronic obstructive pulmonary disease (COPD) medications prescribed before surgery in patients with early-stage non–small cell lung cancer (NSCLC) were associated with both short- and ...
COPD can make it hard for you to breathe. Learn which treatments can help you get active again.
SGLT2 inhibitors and GLP-1 receptor agonists were associated with fewer exacerbations of COPD in adults with type 2 diabetes. There was little difference between SGLT2 inhibitors and GLP-1 ...
In the first half of 2024, many posts on X, formerly Twitter, from U.S. health care professionals discussing COPD therapies focused on ventilation support, medications and palliative care ...
People with schizophrenia are more likely to develop chronic obstructive pulmonary disease (COPD), suggesting a possible ...
Depression correlated with decreased adherence to COPD maintenance medications in an adjusted regression model (odds ratio, 0.93; 95% confidence interval, 0.89 to 0.98).
Lower risk for COPD exacerbations seen with SGLT-2 inhibitors and GLP-1 receptor agonists, but not with DPP-4 inhibitors. HealthDay News — For patients with type 2 diabetes (T2D) and chronic ...
6don MSN
Increased patient–provider communication, education about COPD needed to improve patient care
Prioritizing communications between patients and health care providers and increasing patient education about chronic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results